Greenfield Savings Bank Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Greenfield Savings Bank trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 19.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 491 shares of the biopharmaceutical company’s stock after selling 121 shares during the quarter. Greenfield Savings Bank’s holdings in Regeneron Pharmaceuticals were worth $350,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in REGN. State Street Corp grew its position in Regeneron Pharmaceuticals by 1.3% in the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after acquiring an additional 61,277 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 86,013.3% during the third quarter. International Assets Investment Management LLC now owns 880,939 shares of the biopharmaceutical company’s stock worth $926,078,000 after acquiring an additional 879,916 shares during the period. Charles Schwab Investment Management Inc. raised its stake in shares of Regeneron Pharmaceuticals by 1.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 673,261 shares of the biopharmaceutical company’s stock valued at $707,759,000 after acquiring an additional 11,499 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its holdings in Regeneron Pharmaceuticals by 12.4% in the second quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after purchasing an additional 59,769 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in Regeneron Pharmaceuticals by 0.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 340,566 shares of the biopharmaceutical company’s stock worth $357,945,000 after purchasing an additional 2,270 shares during the period. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $716.90 on Tuesday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The stock has a market cap of $78.78 billion, a PE ratio of 17.74, a P/E/G ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 1 year low of $666.25 and a 1 year high of $1,211.20. The stock has a fifty day moving average price of $749.20 and a 200 day moving average price of $958.71.

Analyst Upgrades and Downgrades

REGN has been the subject of several analyst reports. Piper Sandler lowered their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a report on Friday, November 1st. Citigroup started coverage on Regeneron Pharmaceuticals in a research note on Thursday, November 14th. They set a “neutral” rating and a $895.00 target price for the company. Sanford C. Bernstein cut their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a report on Tuesday, January 7th. Wolfe Research began coverage on shares of Regeneron Pharmaceuticals in a report on Friday, November 15th. They issued an “outperform” rating and a $1,150.00 target price for the company. Finally, JPMorgan Chase & Co. cut their price target on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. One investment analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $1,037.33.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.